A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier.
Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.
Our Oncotype DX® test for HR+, HER2–, early-stage, invasive breast cancer is standard of care to direct adjuvant chemotherapy treatment decision-making and we serve patients in over 90 countries.
